Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate Guest UserMarch 11, 2019 Facebook0 Twitter LinkedIn0 0 Likes